The
clustered regularly interspaced short palindromic repeats (CRISPR)-based
nucleic acid detection can be combined with recombinase-aided amplification
(RAA) to enable rapid, accurate, and early detection of SARS-CoV-2.
Current CRISPR-based approaches to detecting viral nucleic acid typically
require immense manual operations to transfer RPA amplicons for CRISPR
detection or suffer from compromised sensitivity by mixing the competing
RPA amplification and CRISPR detection. Here, we develop dual-CRISPR/Cas12a-assisted
RT-RAA assay and a ″sample-to-answer″ centrifugal microfluidic
platform that can automatically detect 1 copy/μL of the SARS-CoV-2
within 30 min. This chip separates the amplification (RAA) from detection
(CRISPR), such that sensitivity is maximized and the time consumption
is decreased by a factor of 3. For the 26 positive and 8 negative
clinical SARS-CoV-2 samples, this automated centrifugal microfluidics
achieved 100% accuracy compared to the gold-standard RT-PCR technique.
This point-of-care test, with the advantages of being one-step, automated,
rapid, and sensitive, will have a significant potential for clinical
diagnosis and disease prevention.